Novo Nordisk will cut the U.S. list price of Wegovy by 50% from 2027, also affecting Ozempic & Rybelsus. The move aims to make GLP-1 drugs more accessible amid obesity & diabetes concerns. #NovoNordisk #Wegovy #GLP1 #WeightLossDrugs #DiabetesCare #Healthcare #DrugPriceCut #USHealth